A practical guide to the sections of a clinical WES report, variant nomenclature, ACMG classifications, secondary findings and follow-up.
A genetic report is not simply yes or no
A clinical WES report combines sequencing data, medical information and scientific interpretation. It may contain technical terms such as gene, variant, zygosity, pathogenicity and inheritance pattern. The goal is to explain which findings may account for the patient’s condition.
The report cannot replace a medical examination or genetic counseling. It needs interpretation by the treating clinician or genetics professional.
Patient information, referral reason and method
The report usually identifies the patient and sample, relevant dates, the reason for testing, the methods used and the assay’s limitations. Some laboratories include read-depth statistics, percentage of targeted regions covered and reference sequences or analytical tools.
These details help establish the scope and reliability of testing. If a specific gene is particularly important, ask whether the report provides adequate coverage information for that region.
Gene names, variants and nomenclature
Findings may name a gene—for example, BRCA1—and specify a change using standardized HGVS notation at DNA and possibly protein level. Zygosity indicates whether one or both copies are affected, while family history helps assess the inheritance pattern.
Seeing a well-known gene in a report does not, by itself, mean that the patient has the related condition. The precise variant, its classification and clinical fit matter.
The five commonly used variant classes
Under established clinical frameworks, variants are described as pathogenic, likely pathogenic, uncertain significance (VUS), likely benign or benign. Not every variant in a patient is relevant to the reason for referral.
A VUS means the available evidence is insufficient for a clear conclusion. It generally should not serve as the sole basis for preventive surgery or major treatment decisions. Family studies or additional evidence may help refine its classification.
Primary and secondary findings
Primary findings address the original clinical question—for example, a suspected cause of a neurological or developmental condition. Secondary findings can relate to other medically actionable risks rather than the presenting illness.
Secondary finding policies depend on informed consent, laboratory practice and relevant professional guidance. Patients should be told what may be reported and what choices are available before testing.
Three possible next steps after the result
If a clinically consistent pathogenic finding is identified, the clinician may plan targeted management, counseling and family assessment. If the result is uncertain, further evidence, segregation testing or periodic review may be considered.
If no causal variant is identified, the clinical investigation should not automatically stop. Reassessment of symptoms, coverage and other testing methods may be appropriate.
Frequently asked questions
Does a VUS confirm a disease?
No. A variant of uncertain significance does not establish causation and should be interpreted cautiously.
Does a negative report exclude genetic disease?
No. WES has technical and scientific limitations; the report should be reviewed in its clinical context.
Scientific resources for further reading
For case-specific advice and current laboratory requirements, consult our services or genetic counseling team.
